Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nerve zapping: which side works best for migraines?

NCT ID NCT06894121

Symptom relief Sponsor: Ankara City Hospital Bilkent Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether treating the greater occipital nerve on one side or both sides of the head with pulsed radiofrequency provides better migraine relief. 217 adults with episodic or chronic migraine who did not respond well to preventive medications received the procedure under ultrasound guidance. The main goal was to see how many headache days per month changed over 6 months, along with pain intensity and disability scores.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pulsed radiofrequency treatment of the greater occipital nerve
What this could lead to
If successful, this could show which nerve treatment approach (one side or both sides) works better for reducing migraine days and pain.
What could go wrong
This is a completed study, but results are not yet published. The treatment is a procedure, not a drug, and may not work for everyone. Risks include pain, infection, or nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

217 people

The number who actually took part.

Started

Dec 2024

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 65 years * Followed at the Algology outpatient clinic of Ankara Bilkent City Hospital * Diagnosis of episodic migraine (≥5 attacks per month) or chronic migraine according to ICHD-3 criteria * Inadequate response to migraine preventive medications * Not currently using preventive migraine medication OR no change in medication and/or dosage within the last 3 months * No bleeding or coagulation disorders * No active infection * Not pregnant and not suspected of pregnancy * No history of craniocervical surgery affecting the intervention area * Able to understand the study and provide written informed consent * Able to comply with study procedures and follow-up Exclusion Criteria: * Diagnosis of primary headache other than migraine according to ICHD-3 criteria * Fewer than 5 migraine attacks per month * Headache secondary to comorbid conditions (e.g., uncontrolled hypertension, intracranial lesions) * Interventional migraine treatment within 3 months prior to GON-PRF * Botulinum toxin injection within 3 months prior to GON-PRF * Non-pharmacological migraine treatment (e.g., acupuncture, physical therapy, ozone therapy, cognitive behavioral therapy) within 3 months prior to GON-PRF * Withdrawal of consent at any stage of the study * Failure to attend follow-up visits * Development of any condition that meets exclusion criteria during the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Headache disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

headache disorder migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Headache disorders Migraine, greater occipital nerve pulsed radiofrequency Ultrasound guided nerve block

Contacts and locations

Locations

  • Health Sciences University, Ankara Bilkent City Hospital

    Ankara, Cankaya, 06800, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.